Compounds > 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol
Page last updated: 2024-09-03

4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol and debrisoquin

4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol has been researched along with debrisoquin in 2 studies

Compound Research Comparison

Studies
(4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol)		Trials
(4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol)		Recent Studies (post-2010)
(4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol)		Studies
(debrisoquin)		Trials
(debrisoquin)		Recent Studies (post-2010) (debrisoquin)
701298908917

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bertilsson, L; Dahl, ML; Ekqvist, B; Llerena, A2

Other Studies

2 other study(ies) available for 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol and debrisoquin

ArticleYear
Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers.
    Therapeutic drug monitoring, 1992, Volume: 14, Issue:3

    Topics: Chromatography, High Pressure Liquid; Debrisoquin; Haloperidol; Humans; Hydroxylation; Oxidation-Reduction; Phenotype

1992
Genetic factors in the metabolism of haloperidol.
    Clinical neuropharmacology, 1992, Volume: 15 Suppl 1 Pt A

    Topics: Debrisoquin; Half-Life; Haloperidol; Humans; Hydroxylation; Phenotype

1992